Mumbai, India (CU)_ BDR Pharmaceuticals has introduced ENZALUTAMIDE 160 mg under the brand name BDENZA for patients with prostate cancer. Previously, this medication came in 40 mg and 80 mg doses, with patients required to take two pills daily in accordance with the prescribed dose. The goal of the launch of Enzalutamide 160 mg is to improve efficacy, minimize side effects, and prevent relapses by inhibiting the hormones produced by cancer cells.
Raheel Shah, Director of Business Development at BDR Pharmaceuticals, Mumbai, expressed hopes over the new medication. He said, “Our focused launch of such expanded brand strength will definitely add value to Indian Oncology patients as well as provide opportunity for Medical Physicians to comply with patient outcome and standard treatment protocol. This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high quality standards”.
Adding to the strength of BDR Pharma’s Oncology portfolio is the debut of Enzalutamide 160 mg, which was anticipated by many Indian Oncologists for patient convenience. Patients will now be required to take only one drug a day, decreasing the related stress in an already stressed-out Cancer patient. Shah said, “As a key player in manufacturing of Indian Cancer medicines, BDR Pharmaceuticals propagates pan India affordability and is recognised as a “niche” entity in manufacturing of Pharmaceutical APIs and for the renowned new age formulations”.
In the past 15 years, the BDR Group of companies has progressively developed to become a household brand in the pharmaceutical sector, both domestically and internationally. The firm is identified as a “niche” manufacturer of Pharmaceutical Active Pharmaceutical Ingredients (APIs) and notable new age formulations. The group is significantly reinforced by its two subsidiaries, namely, BDR Pharmaceuticals International Pvt Ltd and BDR Life Sciences Pvt. Ltd. The BDR Group specializes in development in four distinct treatment areas, namely, oncology, critical care, gynecology, and neurology.
